Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16547301 | 0.71 | XDH (0.37) | HTT | |
| SCHEMBL820144 | 0.67 | — | — | |
| SCHEMBL18287212 | 0.66 | RAB9A (0.43) | LMNAHTTRAB9ASMN1; SMN2PSMB5 | |
| SCHEMBL25266417 | 0.66 | F13A1 (0.43) | HTTSMN1; SMN2F13A1PSMB5 | |
| Iodide SCHEMBL31485329 | 0.65 | F13A1 (0.42) | HTTSMN1; SMN2F13A1PSMB5 | |
| SCHEMBL444948 | 0.64 | CYP1A2 (0.42) | LMNASMN1; SMN2PSMB5 | |
| SCHEMBL1316463 | 0.64 | KDR (0.52) | PSMB5 | |
| SCHEMBL29788366 | 0.63 | KDR (0.51) | PSMB5 | |
| SCHEMBL28848948 | 0.63 | KDR (0.51) | PSMB5 | |
| SCHEMBL29070232 | 0.63 | KDR (0.51) | PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130109884-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-05-02 | — | — | US | disclosed |
| EP-2585427-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | Sumitomo Chemical Company Limited (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-03-21 | — | — | US | disclosed |
| WO-2012176930-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-27 | — | — | WO | disclosed |
| WO-2011162404-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MSMO1, MGMT | LMNA 3756/4885HTT 3927/4885RAB9A 4454/4885 |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MGMT, BBOX1 | LMNA 2829/4885HTT 2865/4885RAB9A 3655/4885 |
| US-20130109884-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | ALDH18A1, MCCC2, ALDH7A1 | LMNA 2441/4885HTT 3869/4885RAB9A 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.